In vitro calcium antagonistic and antioxidant effects of Org 13061 and its enantiomers, new potential antiatherosclerotic compounds

Fundamental and Clinical Pharmacology

Volumn 11, Issue 5, 1997, Pages 416-426

  Beaughard, M ^a   Chevalier, A ^a   Dureng, G ^a   Leboeuf, J ^a   Massingham, R ^a   Mazur, A ^b   Rayssiguier, Y ^b   Winslow, E ^a  

^a CERM Centre Europeen de Recherches Mauvernay   (France)

^b CEMAGREF   (France)

Author keywords

Antioxidants; Calcium antagonists; Enantiomers; Human LDL; Org 13061

Indexed keywords

ANTIOXIDANT; CALCIUM ANTAGONIST; DILTIAZEM; NIFEDIPINE; ORG 13061; ORG 13471; ORG 13581; OXIDIZED LOW DENSITY LIPOPROTEIN; PROBUCOL; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM ANTAGONISM; CONTROLLED STUDY; ENANTIOMER; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; VASCULAR RING;

EID: 0030867386     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1997.tb00204.x     Document Type: Article

References (42)

1. Barnhart RL, Busch SJ, Jackson RL. Concentration-dependent antioxidant activity of probucol in low density lipoproteins in vitro: probucol degradation precedes lipoprotein oxidation. J Lipid Res 1989;30:1703-10
2. Bolton TB. Mechanisms of action of transmitters and other substances on smooth muscle. Physiol Rev 1979;59:606-718
3. Breugnot C, Mazière C, Auclair M, Mora L, Ronveaux MF, Salmon S et al. Calcium antagonists prevent monocyte and endothelial cell-induced modification of low density lipoproteins. Free Rad Res Commun 1991;15:91-100
4. +-depolarized guinea-pig atria. Br J Pharmacol 1985; 86:7-17
5. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res 1996;33:181-94
6. Catapano AL. The antiatherogenic potential of calcium antagonists: experimental evidence. J Cardiovasc Pharmacol 1992;20:44-50
7. Chevalier A, Shrivastava R, Beaughard M. Antiproliferative and intracellular lipid lowering effect of some antioxidants in vitro. Fundam Clin Pharmacol 1993;7:7
8. Collins P, Fox K. The pathogenesis of atheroma and the rationale for its treatment. Eur Heart J 1992;13:560-5
9. Daugherty A, Roselaar SE. Lipoprotein oxidation as a mediator of atherogenesis: insights from pharmacological studies. Cardiovasc Res 1995;29:297-311
10. 2+ release during drug induced activation of the rabbit aorta. Pflugers Arch 1974;348:13-22
11. 2+ in the rabbit aorta. J Membr Biol 1977;30:363-80
12. Engstrom JE, Kanin LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992;3:194-202
13. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad Biol Med 1992;13:341-90
14. Esterbauer H, Puhl H, Dieber-Rotheneder M, Waeg G, Rabl H. Effect of antioxidants on oxidative modification of LDL. Ann Med 1991;23:573-81
15. Etingin OR, Hajjar DP. Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells a possible mechanism for its antiatherogenic effect. J Clin Invest 1985;75:1554-8
16. Etingin OR, Hajjar DP. Calcium channel blockers enhance cholesteryl ester hydrolysis and decrease total cholesterol accumulation in human aortic tissue. Circ Res 1990;66:185-90
17. Havel RJ, Eder EH, Bragdon JM. The distribution and chemical composition of ultracentifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-63
18. Henry PD. Calcium antagonists as antiatherogenic agents. Ann NY Acad Sci 1988;522:411-9
19. Henry PD, Bentley KI. Suppression of atherosclerosis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest 1981;68:1366-9
20. Keaney JF, Xu AM, Cunningham D, Jackson T, Frei B, Vita JA. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and Superoxide generation. J Clin Invest 1995;95:2520-9
21. Kjeldsen K, Stender S. Calcium antagonists and experimental atherosclerosis. Proc Soc Exp Biol Med 1989;190:219-28
22. Lichtlen PR, Hugenholtz PG, Raffenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 1990;335: 1109-13
23. Lupo E, Locher R, Weisser B, Vetter W. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with α-tocopherol. Biochem Biophys Res Commun 1994;203:1803-8
24. Meyers DJ, Maloley PA. The antioxidant vitamins: impact on atherosclerosis. Pharmacotherapy 1993;13:574-82
25. 2+ channel blockers (nifedipine, diltiazem and verapamil) against the toxicity of oxidized low density lipoprotein to cultured lymphoid cells. Br J Pharmacol 1992;107:738-44
26. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8
27. Orekhov AN. In vitro models of antiatherosclerotic effects of cardiovascular drugs. Am J Cardiol 1990;66:23-8
28. Orekhov AN. Use of human atherosclerotic cells for optimization of antiatherosclerotic therapy. Agents Actions 1991; 32:130-1
29. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986;314:488-500
30. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9
31. Selley ML, Czeti AL, McGuiness JA, Ardlie NG. Dipyridamole inhibits the oxidative modification of low density lipoprotein. Atherosclerosis 1994;111:91-7
32. Shrivastava R, Chevalier A, Slaoui M, John G. An in vitro method using vascular smooth muscle cells to study the effect of compounds on cell proliferation and intracellular lipid accumulation. Methods Find Exp Clin Pharmacol 1993;15:345-50
33. Sparrow CP, Doebber TW, Olszewski J, Wu MS, Ventre J, Stevens KA et al. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N′-diphenylphenylenediamine. J Clin Invest 1992;89:1885-91
34. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444-9
35. Stein O, Halperin G, Stein Y. Long-term effects of verapamil on aortic smooth muscle cells cultured in the presence of hypercholesterolemic serum. Arteriosclerosis 1987;7:585-92
36. Steinberg D, Parthasarathy S, Casew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24
37. Stoller DK, Grorud CB, van Michalek BS, Buchwald H. Reduction of atherosclerosis with non-steroidal anti-inflammatory drugs. J Surg Res 1993;54:7-11
38. Tasaki H, Yamashita K, Nakashima Y, Kuroiwa A, Tulenko TN. Increase in intracellular calcium ion in smooth muscle cells induced by low-density lipoprotein. Gerontology 1994;40:23-8
39. Waters D, Lesperance J, Franchetich M, Causey D, Theroux P, Chiang YK et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;82:1940-53
40. Weiss GB. Calcium and contractility in smooth muscle. Adv Gen Cell Pharmacol 1977;2:71-154
41. Winslow E, Farmer S, Martorana M, Marshall RJ. The effects of bepridil compared with calcium antagonists on rat and rabbit aorta. Eur J Pharmacol 1986;131:219-28
42. Witztum JL. Role of oxidised low density lipoprotein in atherogenesis. Br Heart J 1993;69:12-8